A Phase I, Placebo-controlled, Randomized, Double Blind, Single or Multiple Dose Study of URC102 in Healthy Male Volunteers of Korean and Caucasian to Assess Safety, Pharmacokinetics and Pharmacodynamics
Latest Information Update: 10 May 2019
At a glance
- Drugs URC 102 (Primary)
- Indications Gout
- Focus Adverse reactions
- Sponsors JW Pharmaceutical
- 05 May 2019 Results evaluating the safety, tolerability, pharmacodynamic, and pharmacokinetic profiles of URC102 after single and multiple oral administration in healthy male subjects, published in the Rheumatology.
- 08 Nov 2017 Results presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
- 06 Mar 2017 Status changed from active, no longer recruiting to completed.